News
IMNN
0.8935
-2.47%
-0.0226
Weekly Report: what happened at IMNN last week (0106-0110)?
Weekly Report · 2d ago
Weekly Report: what happened at IMNN last week (1230-0103)?
Weekly Report · 01/06 11:06
Weekly Report: what happened at IMNN last week (1223-1227)?
Weekly Report · 12/30/2024 11:00
Weekly Report: what happened at IMNN last week (1216-1220)?
Weekly Report · 12/23/2024 11:06
Imunon Receives Buy Rating on Positive FDA Alignment and Promising Clinical Results for IMNN-001
TipRanks · 12/20/2024 17:48
IMUNON, Inc. Advances IMNN-001 for Ovarian Cancer with FDA Alignment on CMC Strategy Ahead of Phase 3 Trial
Barchart · 12/19/2024 17:24
Imunon Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Dow Jones · 12/19/2024 17:04
HC Wainwright & Co. Reiterates Buy on Imunon, Maintains $12 Price Target
Benzinga · 12/19/2024 16:54
Imunon Is Maintained at Buy by D. Boral Capital
Dow Jones · 12/19/2024 13:41
Imunon Price Target Maintained With a $29.00/Share by D. Boral Capital
Dow Jones · 12/19/2024 13:41
Imunon announces positive outcome of Type C CMC meeting with FDA on IMNN-001
TipRanks · 12/19/2024 13:10
IMUNON INC - TO INITIATE PHASE 3 TRIAL OF IMNN-001 IN Q1 2025
Reuters · 12/19/2024 13:05
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer
Barchart · 12/19/2024 07:05
Weekly Report: what happened at IMNN last week (1209-1213)?
Weekly Report · 12/16/2024 11:07
Strong Potential for Imunon’s IMNN-001 in Advanced Ovarian Cancer: Promising OVATION 2 Study Results
TipRanks · 12/11/2024 11:16
IMUNON, Inc. Reports Increased Overall Survival in Advanced Ovarian Cancer Patients Treated with IMNN-001
Barchart · 12/10/2024 17:22
Imunon Is Maintained at Buy by D. Boral Capital
Dow Jones · 12/10/2024 14:32
Imunon Price Target Maintained With a $29.00/Share by D. Boral Capital
Dow Jones · 12/10/2024 14:32
D. Boral Capital Maintains Buy on Imunon, Maintains $29 Price Target
Benzinga · 12/10/2024 14:22
Imunon announces additional data from results from Phase 2 OVATION 2 study
TipRanks · 12/10/2024 13:36
More
Webull provides a variety of real-time IMNN stock news. You can receive the latest news about Imunon Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMNN
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunon’s DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.